Back Other Health News

Other Infections

WCLH 2015: Death During MDR-TB Treatment More Likely in HIV+ and Underweight Patients

People living with HIV, those who are underweight, and those with more extensive drug resistance are more likely to die during treatment for multidrug-resistant tuberculosis (MDR-TB) in a 9-country study, according to a presentation at the 46th Union World Conference on Lung Health in Cape Town this month.

alt

Read more:

WCLH 2015: 9-Month Regimen Cures 82% of People with Multidrug-resistant TB in African Study

A 9-month standardized treatment regimen for multidrug-resistant tuberculosis (MDR-TB) cured 82% of people recruited to an observational study in Francophone Africa, according to a presentation at the 46th Union World Conference on Lung Health last week in Cape Town. The regimen showed similar effectiveness to the performance of 9-month MDR-TB treatment regimens in previous studies in Africa and Bangladesh, and with the exception of hearing loss, serious adverse events were rare.

alt

Read more:

EACS 2015: 3-Month Isoniazid/Pyrazinamide Regimen Prevents TB in People with HIV

A daily 3-month regimen of isoniazid and pyrazinamide is just as effective at preventing the development of active tuberculosis (TB) in people living with HIV as a 6-month course of isoniazid alone, according to findings from a Russian study presented by Zinaida Zagdyn at the 15th European AIDS Conference last week in Barcelona.

alt

Read more:

WCLH 2015: TB Treatment Advancing, but Not Reaching All Who Need It

Tuberculosis (TB) treatment has seen some promising recent advances -- including the promise of shorter regimens for multidrug-resistant TB and better therapies for children -- but still not enough is being done to provide access to prevention and treatment for all who need it, according to presentations at the 46th Union World Conference on Lung Health taking place this week in Cape Town.

alt

Read more:

DHHS Proposes Rule Banning Health Service Discrimination Against Transgender People

The U.S. Department of Health and Human Services (DHHS) last week introduced a regulation that would prohibit discrimination in healthcare access and insurance coverage on the basis of sex or gender identity, including denial of services related to gender transition or reassignment. The proposal also requires healthcare providers to improve communication services for people with disabilities or limited English language proficiency.

alt

Read more:

EACS 2015: Newest MDR-TB Drug Prices Could Fall by Up to 95% Through Generic Production

The cost of newer drugs for the treatment of multidrug-resistant tuberculosis (MDR-TB) could be cut by up to 95% if generic production of patented products could be achieved in the same way as for antiretroviral drugs, according to a study presented at the 15th European AIDS Conference last month in Barcelona. Price reductions might permit a 10-fold increase in the number of people who can be treated for MDR-TB within current budgets, without any new funding, the study suggests.

alt

Read more:

CDC Releases Updated Sexually Transmitted Disease Treatment Guidelines

In June the U.S. Centers for Disease Control and Prevention (CDC) published updates guidelines for the treatment of sexually transmitted diseases (STDs). The guidelines include information on more than 2 dozen different sexually transmitted infections, as well as STD complications such as pelvic inflammatory disease and cervical and anal cancer.

alt

Read more:

EACS 2015: TB Death Rate 4-Fold Higher in Eastern Europe Due to Lack of Treatment after Diagnosis

People living with HIV in Eastern Europe who develop tuberculosis (TB) are 4 times more likely to die within a year when compared to similar patients in Western and Southern Europe, or Latin America, a large international study presented at the 15th European AIDS Conference last month in Barcelona has shown. The study found that even after taking into account the prevalence of resistance to first-line TB drugs and receipt of appropriate treatment, people in the other regions were around 70% less likely to die during the year following a TB diagnosis than those in Eastern Europe.

alt

Read more:

Single Dose of Human Papillomavirus Vaccine May Prevent Most Cervical Cancer

Just 1 dose of the Cervarix human papillomavirus (HPV) vaccine was able to protect 85% of young women against cancer-causing HPV types 16 and 18, suggesting that it could prevent a majority of cervical cancer cases, including in settings were administration of the full 3-dose series is difficult, according to an analysis of data from 2 large trials published in the June 9 edition of Lancet Oncology.

alt

Read more: